Bafna Pharmaceuticals Limited (NSE:BAFNAPH)
262.91
+5.15 (2.00%)
Jul 31, 2026, 3:15 PM IST
Bafna Pharmaceuticals Revenue
In the fiscal year ending March 31, 2026, Bafna Pharmaceuticals had annual revenue of 1.51B INR with 3.26% growth. Bafna Pharmaceuticals had revenue of 422.39M in the quarter ending March 31, 2026, with 8.14% growth.
Revenue
1.51B
Revenue Growth
+3.26%
P/S Ratio
4.13
Revenue / Employee
3.71M
Employees
406
Market Cap
6.22B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 1.51B | 47.60M | 3.26% |
| Mar 31, 2025 | 1.46B | -66.09M | -4.33% |
| Mar 31, 2024 | 1.52B | 371.16M | 32.18% |
| Mar 31, 2023 | 1.15B | 302.10M | 35.48% |
| Mar 31, 2022 | 851.40M | 139.22M | 19.55% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Indoco Remedies | 18.73B |
| Solara Active Pharma Sciences | 14.31B |
| Windlas Biotech | 9.04B |
| Ind-Swift Laboratories | 6.41B |
| Sigachi Industries | 4.86B |
| Beta Drugs | 4.10B |
| Jagsonpal Pharmaceuticals | 2.94B |
| Sakar Healthcare | 2.72B |
Bafna Pharmaceuticals News
- 2 months ago - Bafna Pharmaceuticals Quarterly report: Q4 2026 - Filings
- 6 months ago - Bafna Pharmaceuticals Quarterly report: Q3 2026 - Filings
- 9 months ago - Bafna Pharmaceuticals Quarterly report: Q2 2026 - Filings
- 1 year ago - Bafna Pharmaceuticals Quarterly report: Q1 2026 - Filings